AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca has initiated a Phase I clinical study titled ‘A Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)’. The study aims to assess how renal impairment affects the pharmacokinetics, safety, and tolerability of Opemalirsen, a new drug candidate, compared to individuals with normal renal function. This research is significant as it could lead to better treatment options for patients with varying degrees of renal impairment.
The intervention being tested is Opemalirsen (AZD2373), administered as a single subcutaneous injection. This drug is designed to evaluate its safety and effectiveness in participants with different levels of renal function.
The study is non-randomized and follows a parallel-group design, meaning participants are divided into groups based on their renal function. There is no masking involved, and the primary purpose is to gather data on the drug’s pharmacokinetics and safety.
The study began on July 28, 2025, with the latest update on August 27, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
This study could have significant market implications for AstraZeneca, potentially boosting its stock performance if the results are favorable. It also positions the company strategically in the renal impairment treatment market, where competition is growing.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.